Masimo shares hold rating amid potential short-term challenges

On Friday, a financial analyst from Needham maintained a Hold rating on shares of Masimo Corp . (NASDAQ:MASI), a medical technology company. The analyst's statement highlighted expectations that the involvement of Politan, an investment firm, could add value to Masimo over time.

However, there are concerns about potential short-term challenges following the company's first proxy fight with Politan, which led to a significant reduction in its financial guidance.

The analyst pointed out that while the departure of Masimo's CEO Joe Kiani and COO Bilal Muhsin could lead to other key employees leaving, it is unlikely that all 300 employees will do so. The statement also raised the possibility that a new management team could uncover additional issues that may require time and effort to address.

Masimo's consumer audio business was another point of concern, as its sale could potentially dilute the company's earnings per share (EPS), depending on the valuation achieved. The analyst's commentary suggests that while there is potential for value creation, there are several factors that could pose challenges to Masimo in the near future.

The company's stock rating remains unchanged as the analyst suggests a cautious approach due to the uncertainties surrounding Masimo's management changes and business strategy adjustments. This Hold rating indicates a neutral position, implying that investors should maintain their current holdings of Masimo shares without making additional investments at this time.

In other recent news, Masimo Corporation has seen significant developments, including a strong financial performance with a 23% year-over-year increase in healthcare revenue. This growth, driven by robust hospital conversions and a rise in hospital admissions, has also led to new hospital conversion contracts worth $134 million.

Simultaneously, Masimo is exploring the potential separation of its consumer business, with options such as a joint venture, sale, or spinoff under consideration. The company has received unsolicited interest from potential buyers for its consumer audio business.

Masimo's Board has been under scrutiny with Politan's nominees, Bill Jellison and Darlene Solomon, being elected based on preliminary results. However, Masimo's director nominees, Joe Kiani and Christopher Chavez, have received endorsement from proxy advisory firm Egan-Jones. The firm has expressed concerns about a potential management change if Politan wins the proxy fight.

Amid these developments, analyst firms Piper Sandler, Stifel, and BTIG have maintained positive ratings on Masimo's shares. Piper Sandler retained its Overweight rating on Masimo shares with a price target of $165. These recent developments underline the ongoing activities within Masimo Corporation.

InvestingPro Insights

As Masimo Corp. (NASDAQ:MASI) navigates through a period of transition and uncertainty, real-time data and insights from InvestingPro provide a deeper understanding of the company's financial health and market position. According to InvestingPro data, Masimo has a market capitalization of $6.15 billion and a high price-to-earnings (P/E) ratio of 75.45, which suggests investors are currently paying a premium for its earnings.

Adjusted for the last twelve months as of Q2 2024, the P/E ratio stands slightly lower at 67.85. Despite a quarterly revenue growth of 9.01% in Q2 2024, the company experienced a revenue decline of 7.76% over the last twelve months, indicating potential challenges in sustaining growth.

InvestingPro Tips also shed light on the company's financial prospects and valuation. Analysts predict that Masimo will be profitable this year, which aligns with the optimism expressed by the Needham analyst regarding the potential value Politan's involvement could bring.

However, it is important to note that four analysts have revised their earnings downwards for the upcoming period, which might reflect the concerns about the company's recent management changes and the impact of the proxy fight. Moreover, Masimo is trading at high EBIT and EBITDA valuation multiples, which investors should consider in the context of the company's overall financial stability and growth prospects.

For those considering an investment in Masimo or seeking to understand the current valuation better, there are 11 additional InvestingPro Tips available at https://www.investing.com/pro/MASI. These tips provide a comprehensive analysis that could inform investment decisions, especially in light of the company's recent challenges and the potential for future profitability.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.